Cornelia Vogt

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP

Published: May 13, 2026

Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors.

Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors.

Journal: Science advances

Published: February 04, 2026

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Journal: Haematologica

Published: September 11, 2025

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Journal: Leukemia

Published: August 15, 2025

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Journal: Clinical epigenetics

Published: July 03, 2025

Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.

Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.

Journal: Haematologica

Published: November 01, 2024

Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.

Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.

Journal: HemaSphere

Published: August 07, 2024

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.

Journal: British journal of haematology

Published: March 18, 2024

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.

Journal: Haematologica

Published: February 01, 2024

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

Journal: HemaSphere

Published: November 19, 2023

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Journal: Communications biology

Published: July 03, 2023

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.

Journal: Biomarker research

Published: February 07, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026